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Summary
 
H-2K mice injected, intravenously in saline or intraperitoneally in incomplete Freund’s adjuvant,
with large quantities of the immunodominant I-E
 
k
 
–restricted epitope from moth cytochrome c
(MCC) 88–103 fail to respond to subsequent immunization with this epitope when adminis-
tered in complete Freund’s adjuvant. This state of tolerance can be broken by immunization
with certain MCC 88–103 analogues that are heteroclitic antigens as assessed on representative
MCC 88–103 specific T cell clones. In this paper, the mechanism of breaking tolerance by het-
eroclitic antigens was investigated. The following observations were made: (a) T cell hybrid-
omas derived from tolerance-broken animals required higher concentrations of MCC 88–103
to be stimulated than hybridomas derived from normal immune animals, suggesting that they
have T cell receptors (TCRs) of lower affinity; (b) in contrast to normal immune animals
whose MCC-specific TCRs are typically V
 
b
 
3
 
1
 
/V
 
a
 
11
 
1
 
, none of the hybridomas derived from
tolerance-broken animals expressed V
 
b
 
3, although they were all V
 
a
 
11
 
1
 
. Also, the V
 
b
 
 comple-
mentarity determining region 3 (CDR3) regions from the tolerance-broken animals did not
contain the canonical structure and length characteristics of the normal MCC 88–103 immune
repertoire; and (c) adoptive transfer and tolerization of MCC-specific V
 
b
 
3
 
1
 
/V
 
a
 
11
 
1
 
 transgenic
T cells followed by immunization with heteroclitic antigen failed to terminate the state of tol-
erance. Collectively, these data strongly suggest that the mechanism involved in breaking toler-
ance in this system is the stimulation of nontolerized, low-affinity clones, rather than reversal of
anergy. Further support for this mechanism was the finding that after activation, T cells appar-
ently have a lowered threshold with respect to the affinity of interaction with antigen required
for stimulation.
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T
 
he definition of the mechanisms by which tolerance is
established to an antigen, and once established, the
mechanisms by which tolerance can be terminated, are
fundamental to understanding the generation of autoim-
mune responsiveness. Many examples exist that document
the potential of peptides structurally related to self-antigens
to induce an immune response that is cross-reactive with
the self-epitope (1–7). However, the mechanism by which
tolerance is broken in most instances is poorly understood.
T cell tolerance to self-determinants may be mediated by
a variety of mechanisms that act centrally on developing T
cells in the thymus or on mature T cells in the periphery.
Clonal deletion appears to be the dominant mechanism by
which central tolerance is achieved to self-proteins that are
presented within the thymus (8–10). However, this process
may be incomplete or the self-antigen may not be pre-
sented within the thymus, resulting in the appearance of
potentially autoreactive T cells in the periphery. Tolerance
in the periphery may be achieved by a variety of mecha-
nisms, including clonal deletion, anergy, and ignorance (in
which the epitope is not presented in sufficient quantity by
a professional APC to achieve T cell activation). These di-
rect and cell-intrinsic mechanisms are further complicated
by regulatory mechanisms such as suppression and immune
deviation (11–20). Many of the previous studies of periph-
eral self-tolerance have been difficult to interpret because
of not having suitable nontolerized control animals with
which to compare the results obtained in self-antigen ex-
pressing animals. The generation of self-antigen knockouts
and the use of foreign antigen transgenic mice have made 
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the appropriate studies more feasible than previously.
However, even in these systems, since both central and pe-
ripheral mechanisms may be operative, a detailed mecha-
nistic study of peripheral tolerance is difficult. In contrast,
studies of peripheral tolerance to foreign antigens have es-
tablished that both cell death and anergy can be involved in
the generation of tolerance under circumstances where the
fate of tolerized transgenic T cells can be followed with an-
ticlonotypic antibodies (21–25).
We have initiated the study of a model of adult tolerance
to a foreign immunodominant epitope and have analyzed
the breaking of that tolerance by structurally related, cross-
reactive antigens so that we could gain information on the
mechanism by which peripheral T cell tolerance is estab-
lished and on how molecular mimicry may operate in the
breaking of peripheral tolerance. Using the I-E
 
k
 
–restricted
epitope moth cytochrome c 88–103 (pMCC)
 
1 
 
as the tol-
erogen, it was found that certain single amino acid–substi-
tuted analogues of the tolerogen were capable of breaking
tolerance to the antigen (26). The successful analogues
were all heteroclitic antigens, in that they stimulated a rep-
resentative pMCC-specific T cell clone at a lower concen-
tration than that required for the cognate antigen. Immune
deviation was excluded as a possible mechanism in the es-
tablishment and the termination of the tolerant state in this
system. In this study, two other possible mechanisms for
breaking tolerance were evaluated: (a) the stimulation of a
subset of T cells that, because they possessed too low an af-
finity for the tolerogen, had escaped tolerance induction;
and (b) the reactivation of previously anergized T cells.
The accumulated data strongly support the first mecha-
nism, namely the activation of T cells that were of too low
affinity to be tolerized, but once stimulated by the hetero-
clitic antigen became responsive to subsequent stimulation
with the tolerizing epitope.
 
Materials and Methods
 
Animals and Cell Lines.
 
Female B10.A mice (The Jackson
Laboratory) were used at 8–10 wk of age. Invariant chain–defi-
cient B10.BR mice were provided by Dr. D. Mathis (IGBMC,
Strasbourg, France) and used at 6–12 wk of age. AND and AD10
transgenic mice containing pigeon cytochrome c (PCC)–specific
TCRs were provided by Dr. S. Hedrick (University of California,
San Diego, CA), as was the cytochrome c–specific T cell clone,
AD10. The B cell lymphoma CH27, provided by Dr. G. Hough-
ton (University of North Carolina, Chapel Hill, NC), was used as
APC in some experiments. For IL-2 determinations, the IL-2–
dependent T cell line CTLL-2 was used. BW5147
 
a
 
2
 
b
 
2
 
 cell line
was used as fusion partner in the production of T cell hybridomas.
 
Peptide Synthesis.
 
pMCC (ANERADLIAYLKQATK) and
the heteroclitic analogue (pMCC-A; AAAAAAAIAYAKQATK)
were synthesized on a Rainin Symphony synthesizer (Peptide
Technologies) as described previously (27). Peptides were puri-
fied by reverse-phase HPLC to 
 
.
 
95% purity. Identity of the pep-
tides was substantiated by mass spectrometry.
 
Tolerance Induction and Immunization.
 
Tolerance induction
and immunization were performed as described previously (26).
In brief, to induce tolerance, B10.A mice were injected intraperi-
toneally with 300 
 
m
 
g pMCC in IFA (Pierce Chemical Co.). 10 d
later, tolerized mice were immunized with 20 
 
m
 
g pMCC or the
heteroclitic antigen analogue, pMCC-A, in CFA (Difco) subcu-
taneously in the base of the tail. As controls, normal mice were
immunized with 20 
 
m
 
g pMCC or pMCC-A in CFA. 10 d after
immunization, draining lymph nodes were removed and single
cell suspensions were made and used for proliferation and cyto-
kine assays or to establish short-term T cell lines and hybridomas.
 
Proliferation Assays.
 
Cells from draining lymph nodes (para-
aortic and inguinal) were plated at 2.5 
 
3
 
 10
 
5
 
 cells/well along
with 2.5 
 
3
 
 10
 
5
 
 irradiated (3,000 rad) syngeneic splenocytes and
stimulated with the pMCC or pMCC-A peptide as indicated. Af-
ter 72 h, the cultures were pulsed for an additional 18 h with 1
 
m
 
Ci of [
 
3
 
H]thymidine and analyzed by beta-plate scintigraphy. In
experiments to analyze relative immunogenicity of MCC ana-
logues, proliferation assays were performed using the AD10
clone, as described previously (27).
 
Cytokine Assays.
 
For cytokine analysis, supernatants from the
cultures that had been established to measure the proliferative re-
sponse were removed after 24 h for IL-2 measurement, after 48 h
for IL-4 and IL-10, or after 72 h for IFN-
 
g
 
. IL-2 was measured
by bioassay using the CTLL-2 cell line. IL-4, IL-10, and IFN-
 
g
 
were assayed by ELISA according to the instructions provided by
the manufacturer of the reagents (PharMingen). The sensitivities
of the ELISA assays were as follows: IFN-
 
g
 
, 100 pg/ml; IL-4, 50
pg/ml; and IL-10, 50 pg/ml.
 
I-E
 
k
 
 Binding Assay.
 
Peptides were analyzed for their ability to
bind to purified I-E
 
k
 
 molecules as described previously (28). The
binding capacity is reported as the concentration of peptide re-
quired to obtain 50% inhibition (IC
 
50
 
) of binding of the radiola-
beled ligand.
 
Adoptive Transfer of MCC-specific Transgenic T Cells.
 
CD4
 
1
 
 T
cells were purified from the lymph node and spleen of pMCC-
specific TCR transgenic mice (AND) by collecting nonadherent
cells from a nylon wool column, followed by complement treat-
ment of the cells that had previously been incubated with anti-
bodies to CD8 (3.155), heat-stable antigen (JIID), class II MHC
(M5/114 and CA-4.A12), macrophages (M1/70), and dendritic
cells (33D1), and subsequently cross-linked with mouse anti–rat
kappa antibody (MAR18.5). The percentage of CD4
 
1
 
 cells that
were V
 
a
 
11
 
1
 
V
 
b
 
3
 
1
 
 T cells was determined by flow cytometry.
This information was then used to calculate the total number of
cells that had to be injected to achieve 2.5 
 
3
 
 10
 
6
 
 V
 
a
 
11
 
1
 
V
 
b
 
3
 
1
 
 T
cells/injection. Mice were injected intravenously with this num-
ber of cells in a vol of 0.4 ml of HBSS (GIBCO BRL) (21). Re-
cipient mice were unirradiated, invariant chain–deficient B10.Br
mice. 3 d after cell transfer, the animals were injected intra-
venously with 300 
 
m
 
g of pMCC in a vol of 250 
 
m
 
l to induce
tolerance. 10 d later, tolerized and nontolerized mice were im-
munized with 20 
 
m
 
g of pMCC or pMCC-A in CFA subcutane-
ously. After an additional 10 d, draining lymph nodes were
removed and single cell suspensions were used for in vitro stimu-
lation and cytokine analysis.
 
T Cell Hybridomas.
 
Draining lymph node cells from immu-
nized or tolerance-broken mice were restimulated in vitro with
0.5 
 
m
 
M pMCC or pMCC-A for 2 d and expanded with IL-2 (20
U/ml) for an additional 2 d. The lymphoblasts thus generated
were fused with the BW5147
 
a
 
2
 
b
 
2
 
 cell line at 
 
z
 
1:3 ratio, and
hybridomas were selected in HAT medium and distributed in
96-well plates at 
 
z
 
10
 
4
 
 cells/well (29). Wells were screened for
 
1
 
Abbreviations used in this paper:
 
 BI, beef insulin; MCC, moth cytochrome c;
pMCC, MCC 88–103; pMCC-A, pMCC heteroclitic polyalanine analogue. 
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reactivity to pMCC or pMCC-A by measuring IL-2 production.
The positive wells were cloned at a concentration of 0.3 cells/
well, and clones that produced IL-2 in response to antigen were
expanded for further analysis.
 
Flow Cytometry.
 
Cells were incubated on ice with anti-CD3–
FITC, anti-V
 
a
 
11–FITC, anti-V
 
b
 
3–PE (PharMingen), or anti-
CD4–PE (Becton Dickinson) for 1 h and washed several times.
Live cells were gated by forward and side scatter and analyzed by
flow cytometry on a FACScan™ equipped with CELLQuest™
software (Becton Dickinson).
 
DNA Sequence Analysis.
 
Total RNA was isolated from T cell
hybridomas using an RNeasy Mini Kit (QIAGEN) according to
the manufacturer’s instructions. Oligo dT–primed cDNA was
synthesized using a cDNA Cycle kit (Invitrogen Corp.) following
the manufacturer’s protocol and then amplified by PCR for se-
quence analysis. The predicted size fragments from PCR amplifi-
cation were further purified with a QIAquick Gel Extraction kit
(QIAGEN) and sequenced using the Taq Dye Deoxy Termina-
tor Cycle Sequencing kit (Applied Biosystems) on an Applied
Biosystems 310 DNA Sequencer. The PCR and sequencing
primers used were as follows: for 
 
a
 
 chain PCR: C
 
a
 
, AAG TCG
GTG AAC AGG CAG AG; for V
 
a
 
11, TCA GGA ACA AAG
GAG AAT GG; for 
 
a
 
 chain sequencing: C
 
a
 
, AAC TGG TAC
ACA GCA GGT TC; for 
 
b
 
 chain PCR primers: C
 
b
 
, AGC ACA
CGA GGG TAG CCT T (30); for 
 
b
 
-chain sequencing: GGA
GTC ACA TTT CTC AGA TCC A. A set of V
 
b
 
 primers was
used for PCR as reported previously (31).
 
Results
 
In a previous study to determine whether cross-reactive
antigen analogues could break tolerance induced to the im-
munodominant T cell epitope from MCC, pMCC, it was
found that certain heteroclitic antigens (as defined by their
heightened antigenicity for a representative T cell clone)
were capable of breaking tolerance (26). Specifically, sub-
stitutions at the minor MHC contact residue L98 were ef-
fective in this regard. In this study, we have used a pMCC
analogue with an L98A substitution that also had residues
88–94, which are outside the MHC peptide binding cleft,
substituted with alanines. This poly-A MCC analogue
(pMCC-A) had a similar binding capacity to I-E
 
k
 
 as the na-
tive peptide, but was able to stimulate MCC-specific clones
 
z
 
10-fold more efficiently than the native pMCC peptide
(Table I). The ability of this analogue to break tolerance to
pMCC is shown in Fig. 1. Tolerized animals had a mark-
edly reduced capacity to proliferate in response to stimula-
tion with pMCC compared with the response of immu-
nized controls (Fig. 1 A) and did not synthesize detectable
amounts of IFN-
 
g
 
 (Fig. 1 B) or other cytokines such as IL-2,
IL-4, or IL-10 (data not shown). In contrast, mice that
were tolerized to pMCC and then immunized with the
heteroclitic analogue, pMCC-A, mounted vigorous prolif-
erative and cytokine responses, albeit requiring 10–100-
fold more antigen than the normal immunized controls to
achieve comparable responses.
Because of reports that claim administration of antigen
intraperitoneally in IFA leads to sequestration of the im-
mune response in the spleen rather than tolerance induc-
tion, studies were carried out to evaluate this possibility.
Cytokine analysis of spleen and draining lymph nodes after
pMCC administration intraperitoneally in IFA followed by
pMCC immunization subcutaneously in CFA indicated
 
Table I.
 
MHC Binding and Antigenicity of pMCC
and pMCC-A
 
Sequence
I-E
 
k
 
binding
 
*
 
Antigenicity
 
‡
 
nM nM
 
pMCC ANERADLIAYLKQATK 31 2.8
pMCC-A AAAAAAAIAYAKQATK 36 0.3
 
*
 
Concentration of peptide required to inhibit by 50% the binding of a
standard radioiodinated peptide to soluble I-E
 
k
 
.
 
‡
 
Concentration of peptide required to achieve 40% of maximum pro-
liferation of the pMCC-specific T cell clone, AD10.
Figure 1. Capacity of a heteroclitic anti-
gen analogue to terminate tolerance. The
heteroclitic antigen pMCC-A and the cog-
nate antigen pMCC were used to immunize
mice that had been previously tolerized
to pMCC. Lymphoid cells from nontoler-
ized, pMCC-immunized mice (m), toler-
ized and pMCC-immunized mice (r), and
tolerized and pMCC-A–immunized mice
(j) were analyzed for their proliferative ac-
tivity and production of IFN-g after in vitro
stimulation with the tolerogen, pMCC. 
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that tolerance was evident in both lymph node and spleen,
with undetectable quantities of IFN-
 
g
 
 and IL-4 found in
culture supernatants of both organs. Enzyme-linked immu-
nospot (ELISPOT) analysis also indicated tolerance induc-
tion, although less dramatic than the supernatant analysis.
IFN-
 
g
 
–producing cells predominated in normal immune
lymph node and spleen (600 and 500 cells/10
 
6
 
), respec-
tively, with a very small IL-4–producing population (
 
,
 
20
cells/10
 
6
 
). In pMCC-tolerized and immunized animals,
there was a 60 and 75% reduction in IFN-
 
g
 
–producing
cells in both spleen and lymph node, with no change or a
slight increase in IL-4–producing cells (24 cells/10
 
6
 
 in
spleen). Thus, with respect to proliferation and the major
cytokine, IFN-
 
g
 
, tolerance was clearly established by the
protocol used, although the small number of IL-4–produc-
ing cells generated was apparently not affected by the toler-
ance-inducing protocol.
 
Clonal Analysis of T Cells Involved in Termination of Toler-
ance.
 
The results shown in Fig. 1 and those reported pre-
viously (26) suggest that the T cells involved in the break-
ing of tolerance have a lower avidity for antigen compared
with normal immune T cells, as evidenced by the shift in
the antigen dose–response profile. To study in greater de-
tail the functional activity of the T cells involved in the
breaking of tolerance to pMCC, and in order to analyze
the structure of their TCRs, a series of T cell hybridomas
was made from animals whose tolerance to pMCC was
broken by immunization with pMCC-A. As controls, hy-
bridomas were also derived from normal animals immu-
nized with either pMCC or pMCC-A. The response of
representative hybridomas derived from normal or toler-
ance-broken animals to stimulation with pMCC is shown
in Fig. 2. The two hybridomas derived from pMCC or
pMCC-A normal immune animals behaved similarly to
stimulation with pMCC. In contrast, and similar to the data
obtained with the bulk T cell response, the hybridoma de-
rived from the tolerance-broken group required 
 
z
 
10-fold
more pMCC to give an IL-2 response comparable to that
of the hybridomas derived from the normal immunized an-
imals. The decreased antigen responsiveness of the hybri-
domas derived from tolerance-broken animals was not due
to a decrease in surface expression of either the TCR or the
CD4 coreceptor (Fig. 2, B and C; and data not shown).
Fig. 3 summarizes the antigen response data from all hy-
bridomas that reacted to both pMCC and pMCC-A, as a
plot of the quantity of pMCC versus pMCC-A required to
generate an IL-2 response in each hybridoma analyzed.
Several conclusions can be derived from the data shown in
Fig. 3. (a) All but one of the hybridomas derived from the
pMCC-immunized group responded to lower concentra-
tions of pMCC-A than pMCC, as evidenced by a location
on the graph below the diagonal. This indicates that the
heteroclitic nature of pMCC-A, originally described with a
single T cell clone, is generalizable to the majority of the
pMCC-specific T cell repertoire. (b) The hybridomas in
the pMCC tolerance-broken group, in general, required
higher concentrations of pMCC to stimulate an IL-2 re-
sponse than the hybridomas from either the pMCC or
pMCC-A normal immune groups. Thus, the hybridomas
from the tolerance-broken group required an average of
0.88 
 
m
 
M of pMCC to stimulate an IL-2 response, whereas
the pMCC immune group required 0.01 
 
m
 
M, and the
pMCC-A immune group required 0.07 
 
m
 
M pMCC to
stimulate a response. (c) In contrast to the greater antigen
requirement of the tolerance-broken group for pMCC, the
response to pMCC-A was similar for all three groups. In
addition to the cross-reactive hybridomas shown in Fig. 3,
a small number of hybridomas from pMCC or pMCC-A
immune animals were found to be non–cross-reactive (1 of
10 in the pMCC immune group failed to respond to
pMCC-A, and 3 of 14 of the pMCC-A group failed to re-
spond to pMCC; data not shown).
 
Structural Characteristics of the TCRs from T Cells Involved
in the Breaking of Tolerance to pMCC.
 
The antigen dose–
response data for pMCC indicated that the hybridomas
from the tolerance-broken group had a lower avidity for
pMCC than hybridomas from normal immune animals. To
determine if this functional difference between T cells de-
rived from normal and tolerance-broken animals was cor-
related with structural features of the TCR, we undertook
an analysis of their V
 
a
 
 and V
 
b
 
 chains. Since previous stud-
Figure 2. Function and receptor analysis of T cell hybridomas derived
from normal immune and tolerance-broken animals. (A) T cell hybrid-
omas derived from mice which were pMCC (m) or pMCC-A (j) immu-
nized, or tolerized to pMCC and immunized with pMCC-A (r) were
analyzed for their capacity to make IL-2 in response to varying doses of
pMCC. (B and C) T cell hybridomas from pMCC-immunized mice
(light line), pMCC-A–immunized mice (dotted line), and tolerance-bro-
ken mice (bold line) were analyzed for expression of CD3 (B) and CD4
(C). Dashed line indicates negative control staining. 
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ies of the V
 
a and Vb utilization of MCC-specific T cells
indicated that the response to this antigen was dominated
by T cells that express Va11 and Vb3 (32–38), initially
flow cytometric analysis of the T cell hybridomas for ex-
pression of Va11 and Vb3 was performed. Almost one half
(5 of 12) of the T cell clones derived from pMCC-immu-
nized animals were Va111/Vb31, with the rest being ei-
ther Va111/Vb32 (4 of 12) or negative for both Va11 and
Vb3 (3 of 12). The repertoire of clones derived from
pMCC-A immune animals differed somewhat from this
distribution, in that only about one fourth of the clones (3
of 13) possessed the canonical Va111/Vb31 phenotype,
and about one half (7 of 13) were Va111/Vb32. The data
obtained with the T cell clones derived from the tolerance-
broken group were strikingly different, in that all eight
clones analyzed were Va111/Vb32. These data suggest
that the typical Va111/Vb31 MCC-reactive clones were
irreversibly inactivated by the tolerizing dose of pMCC and
did not participate in the termination of tolerance induced
by pMCC-A. Rather, a subset of the Va111/Vb32 clones
responsive to pMCC-A was involved in the breaking of
tolerance.
The difference in the repertoire elicited by pMCC and
pMCC-A immunization with respect to the relative num-
bers of Vb31/Va111 expressing T cells was substantiated
by the analysis of short-term T cell lines (Fig. 4). Whereas
the T cell line generated from pMCC-immunized animals
contained 33% Va111/Vb31 cells and 25% Va111/Vb32
cells, the pMCC-A immune line contained less than half
the percentage of Va111/Vb31 cells (14%) and more than
twice the percentage of Va111/Vb32 cells (59%). These
data are consistent with the data obtained with the T cell
hybridomas derived from pMCC-A–immunized animals
that also demonstrated a skewing toward a Va111/Vb32
phenotype. A second independently derived set of T cell
lines gave similar results.
To further analyze the TCR repertoire involved in
breaking tolerance and to compare it with the repertoire
normally involved in the response to MCC, cDNA se-
quence analysis of the junctional regions encompassing the
CDR3 of the a and b chains was performed, together with
the identification of the Vb families other than Vb3 that
were used (Fig. 5). Previous sequence analyses of the Va11
genes associated with a cytochrome c–specific response in-
dicated that the CDR3 regions were usually 8 residues
long, with a conserved glutamic acid (E) at position 93 and
S, A, or G at position 95 (34–38). Of the 8 Va11 CDR3
regions analyzed from T cell hybridomas derived from
pMCC-immunized animals, all had E at position 93, 5 had
S at position 95, and 6 were 8 residues in length (Fig. 5 A).
Thus, this set of pMCC-specific clones was similar in the
structure of their Va CDR3 regions to previously studied
TCRs. The Va11 CDR3 region from the tolerance-bro-
ken group was, in general, very similar to that of the
pMCC immune group, but with a slightly greater devia-
tion from the canonical structure (Fig. 5 B). Thus, all 8
clones had E at position 93, but only 4 had G or A at posi-
tion 95, and only 4 were 8 residues in length. Of particular
interest was the finding of a 4-asparagine (N) repeat from
positions 95–98 that was present in 4 of the 8 sequences
analyzed. This feature was observed in only one of the se-
quences from the pMCC immune group. The Va11
CDR3 region from the pMCC-A immune group had
characteristics intermediate between the pMCC immune
group and the tolerance-broken group (Fig. 5 C): all 10 se-
quences contained E at position 93, 6 of 10 contained G,
A, or S at 95, 6 of 10 had CDR3 regions 8 residues in
length, and 3 sequences contained the asparagine repeat
from residues 95–98.
With respect to the Vb gene analysis, as described above,
the most striking difference between the pMCC immune
group and the tolerance-broken group was the complete
absence of Vb3 in the latter group of hybridomas. 4 of 8
Va111 TCR genes sequenced in the pMCC immune
group were Vb3, with the other 4 b chains being derived
from Vb8, 14, 15, and 16 gene families (Fig. 5 A). In con-
trast, the tolerance-broken group (Fig. 5 B) expressed
chains from only 2 gene families: Vb16 (3 of 8) and Vb8 (5
of 8). The motif and length of the Vb CDR3 that has been
previously described to be associated with anti-cytochrome
c activity is a length of 9 residues, with N at position 100
and a G or A at position 102 (34–38). In the pMCC im-
mune group, 6 of 8 b chains analyzed had CDR3 regions 9
residues in length, 6 had N at position 100, and 7 had G or
A at 102. In striking contrast to this, none of the 8 Vb
CDR3 regions analyzed from the tolerance-broken group
had a length of 9 residues, and none had N at position 100,
although 4 of 8 had a G or A at 102. Again, the pMCC-A
Figure 3. Responsiveness of T cell hybridomas to pMCC and pMCC-A
stimulation. T cell hybridomas derived from mice that were pMCC (d)
or pMCC-A (s) immunized or mice in which tolerance was terminated
by pMCC-A (u) were analyzed with respect to the concentration of
pMCC and pMCC-A required to stimulate an IL-2 response to pMCC
or pMCC-A. The antigen concentration required for the production
of 20 U IL-2 is shown. Each symbol represents an individual T cell hy-
bridoma.988 Breaking Tolerance to an Immunodominant Epitope by Heteroclitic Antigens Figure 4 (continues on facing page).989 Wang et al.
immune group had characteristics intermediate between
those of the pMCC immune and tolerance-broken groups.
3 of the 10 b chains analyzed were Vb3, with the remain-
der being either Vb8 (2) or Vb16 (5). 4 of the 10 CDR3
regions were 9 residues long, 2 had N at position 100, and
6 contained G or A at 102.
These data suggest the following conclusions: (a) MCC
recognition, even the low-avidity response associated with
the tolerance-broken group, is very strongly associated
with the presence of an a chain from the Va11 family,
with a CDR3 region that has an E at position 93, a residue
previously implicated as being involved in the interaction
with one of the immunodominant TCR contact residues
in pMCC, K99 (39); (b) although the expression of Vb3 is
not necessary for MCC reactivity, it appears to be associ-
ated with the higher avidity interactions of the pMCC-
immunized group; and (c) the lower avidity TCRs found
in the tolerance-broken group expressed Vb8 or Vb16 and
did not contain the canonical N at position 100. Vb16 ex-
pression appeared to be particularly associated with de-
creased avidity for MCC. Two of the three clones from the
pMCC-A immune group that failed to cross-react at all
with pMCC were Vb16, as was the clone with the least
cross-reactivity with pMCC. Also, in the tolerance-broken
group, the two lowest avidity clones for pMCC (requiring
.1 mM MCC for stimulation) expressed Vb16.
The data shown in Figs. 3 and 5 were obtained with hy-
bridomas derived, in the case of the tolerance-broken
group, from a pool of lymphocytes from two animals, and
in the case of the normal immune group, from two separate
fusions of cells from individual mice. A second fusion of
cells from another two tolerance-broken animals was con-
sistent with the data shown in Figs. 3 and 5, in that they
had lower avidity for pMCC than normal immune animals,
and none of them expressed Vb3 (data not shown).
Failure of pMCC-A to Reverse Tolerance of Adoptively
Transferred pMCC-specific Transgenic T Cells. To evaluate
the possibility that breaking tolerance by pMCC-A might
involve reversal of anergy, an adoptive transfer system was
established in which the effect of pMCC-A on the toler-
ance induced in a single clone of cells could be evaluated
(21). For this purpose, T cells from cytochrome c–specific
TCR transgenic mice (AND) were used. The AND TCR
is Vb31/Va111 and recognizes pMCC-A as a heteroclitic
antigen. As recipient mice, H-2K1 invariant chain–defi-
cient animals were used. These animals had previously
been shown to lack a T cell repertoire capable of respond-
ing to pMCC (40, 41). Thus, if tolerance could be broken
in adoptively transferred invariant chain–deficient animals,
the T cells involved would have to have been derived from
the adoptively transferred TCR transgenic cells. In prelim-
inary experiments, the failure of invariant chain–deficient
mice to respond to either pMCC or pMCC-A was con-
firmed (data not shown). These mice were injected with
2.5 3 106 CD41 Vb31/Va111 T cells from AND trans-
genic mice. 3 d after transfer, one group of mice was toler-
ized by the intravenous injection of 300 mg of pMCC. 10 d
after the induction of tolerance, these animals and groups
of nontolerized, adoptively transferred animals were immu-
nized with pMCC or pMCC-A and their immune re-
sponses were evaluated by analyzing the in vitro response
to pMCC of regional lymph nodes harvested 10 d after im-
munization. Adoptively transferred and tolerized mice con-
tained 1.61 6 0.4% Vb31/Va111 T cells, compared with
0.72 6 0.23% Vb31/Va111 cells in mice that did not re-
ceive an adoptive transfer. This difference was significant (P ,
0.01), and therefore it could be concluded that after adop-
tive transfer and tolerance induction, there was a residual
transgenic T cell population derived from the adoptively
transferred transgenic T cells (1.61 – 0.72 5 0.89%) that
could be studied for reversal of anergy. The immune re-
sponse of T cells derived from adoptively transferred, toler-
ized, and subsequently immunized animals is shown in Fig.
6. The data, expressed as the amount of IFN-g per Vb31/
Va111 cell put into culture, indicated: (a) tolerance could
be established in this adoptive transfer system, since animals
that received an intravenous injection of pMCC before im-
munization with pMCC in CFA were severely impaired in
their capacity to produce IFN-g compared with the non-
tolerized controls (0.15 vs. 0.95 pg/cell); and (b) immuni-
zation with the heteroclitic analogue pMCC-A failed to
break this tolerant state.
TCR Antagonist Peptides Can Act as Agonists When Used to
Stimulate Recently Primed T Cells. If the model suggested
by our data is correct, namely that breaking tolerance in-
volves the activation of T cells with low affinity for the
tolerogen but high affinity for the heteroclitic antigen, then
it must be further postulated that these T cells, once stimu-
Figure 4 (continued). Analysis of cytochrome c–specific TCRs. pMCC-reactive Va111 T cell hybridomas derived from (A) pMCC-immunized
mice, (B) pMCC-tolerized and pMCC-A–immunized mice, and (C) pMCC-A immunized mice were analyzed for their Va and Vb CDR3 sequence, J
region usage, length of CDR3 region, and Vb gene family usage.
Figure 5. Va11 and Vb3 expres-
sion in short-term lines from pMCC
and pMCC-A immune mice. Short-
term T cell lines from a pMCC-
immunized animal (A) and pMCC-
A–immunized animal (B) were
analyzed by flow cytometry for the
incidence of Va111 and/or Vb31
cells.990 Breaking Tolerance to an Immunodominant Epitope by Heteroclitic Antigens
lated by the heteroclitic antigen, have a lowered threshold
for stimulation and become responsive to stimulation by
the lower affinity tolerogen. To evaluate this postulate, we
studied the response of naive and recently primed TCR
transgenic T cells to stimulation with either the cognate
antigen used to prime the T cells or a nonantigenic TCR
antagonist analogue of the antigen with presumably lower
affinity for the TCR. T cells from the cytochrome c–spe-
cific TCR transgenic line AD10 were used for this pur-
pose, since this TCR had been extensively analyzed previ-
ously for reactivity to a large panel of pMCC analogue
peptides. Naive T cells or T cells that had been stimulated
with pMCC 8–12 d previously were stimulated with vary-
ing doses of pMCC or the TCR antagonist peptide
T102G, which has a glycine (G) substituted for one of the
major TCR contact residues, T102. The data shown in
Fig. 7 demonstrate that the T102G analogue, which was
nonantigenic for naive T cells, was an agonist when assayed
Figure 6. Failure to break tol-
erance of adoptively transferred
pMCC-specific transgenic T
cells. Lymph node cells from
AND transgenic T cells were in-
jected into invariant chain–defi-
cient B10.BR mice. Animals
were left untreated or were toler-
ized by the intravenous injection
of 300 mg pMCC. Mice were
subsequently immunized with
pMCC or pMCC-A and ana-
lyzed for their responsiveness to
pMCC by measuring their ca-
pacity to produce IFN-g upon
restimulation in vitro. Data are
plotted as the amount of IFN-g
produced per Va111/Vb31 cell
placed into culture.
Figure 7. Capacity of previously primed T cells to respond to TCR antagonist peptides. Naive AD10 transgenic T cells (u) or AD10 cells that had
been stimulated with 0.1 mg/ml of pMCC 12 d previously (j) were stimulated with various quantities of pMCC (left) or the TCR antagonist peptide,
T102G (right), in the presence of CH27 cells as APCs. Proliferation was measured by the incorporation of [3H]thymidine added at day 2 of a 3-d culture.991 Wang et al.
on recently primed T cells, albeit requiring a high concen-
tration (1–100 mg/ml) to achieve this effect.
Discussion
This study was undertaken to evaluate two potential
mechanisms by which antigen analogues might operate in
the termination of T cell tolerance to an immunodominant
epitope: stimulation of low-affinity nontolerized clones and
reversal of anergy. Three sets of data presented in this study
favor the conclusion that the first mechanism is operative.
First, T cell hybridomas derived from tolerance-broken
animals required, on average, 88-fold higher concentration
of antigen than hybridomas derived from normal immune
animals in order to be stimulated to produce IL-2. This dif-
ference in antigen dose requirement is most likely due to
differences in affinity of the TCRs from these two groups
of hybridomas, but other possibilities need to be consid-
ered, such as differences in the levels of expression of mole-
cules that contribute to the stimulation of the T cells; these
include the TCR itself, the CD4 coreceptor, and adhesion
molecules such as LFA-1. Two lines of evidence suggest
that differential expression of these molecules does not
contribute to the antigen dose requirements observed.
First, no correlation between the levels of expression of
TCR and CD4 and the antigen dose requirement for stim-
ulation was observed (Fig. 2; and data not shown). Second,
when I-Ek–transfected fibroblasts that lacked intercellular
adhesion molecule (ICAM), B-7, or other known ligands
for T cell adhesion/costimulator receptors were used as
APC, the large difference in antigen dose requirements for
the tolerance-broken and normal immune animals was still
observed (576 vs. 22 nM).
The second set of data that supports the hypothesis of
stimulation of low-affinity nontolerized clones as a mecha-
nism for breaking tolerance is the finding of a different rep-
ertoire of TCRs on T cells from tolerance-broken animals
and normal immune animals. Although there was no abso-
lutely unique feature to the TCRs from the tolerance-bro-
ken group of hybridomas, there was pronounced skewing
of the TCRs compared with those found in the normal
immune group. Vb3, the major Vb family found in the
normal immune group (33–38), was not represented at all
in the tolerance-broken group. Instead, Vb8 and Vb16
were expressed in the tolerance-broken group—Vb fami-
lies that were only occasionally expressed in the MCC-spe-
cific T cells from normal immune animals. Similarly, the
canonical Vb CDR3 motif and length associated with the
response to pMCC were not observed in any of the Vb
CDR3 regions from the tolerance-broken group of hybrid-
omas. If reversal of anergy were the mechanism for break-
ing tolerance, there is no apparent reason for it to be re-
stricted to a minor subset of clones with the exclusion of
the major Vb31/Va111 subset. On the other hand, a dis-
tinctly different repertoire of TCRs with different Vb/Va
composition would be consistent with a mechanism of
breaking tolerance that involved the stimulation of low-
affinity clones that were not capable of being stimulated af-
ter MCC immunization nor were tolerizable when MCC
was administered in a tolerogenic form.
The third observation in support of the concept that tol-
erance was broken by low-affinity nontolerized clones was
our failure to terminate the tolerant state of adoptively
transferred and tolerized transgenic T cells. When trans-
genic T cells bearing a typical Vb31/Va111 TCR specific
for MCC were transferred and subsequently tolerized to
MCC, the same heteroclitic peptide that was capable of
breaking tolerance in conventional animals failed to break
tolerance in these animals with a clonal population of toler-
ized cells.
Taken together, these three sets of data strongly support
the hypothesis that breaking tolerance involves the stimula-
tion of nontolerized, low-affinity clones by the MCC het-
eroclitic analogue. For reversal of anergy to be operative, it
would be necessary to postulate that certain (Vb31/
Va111) cells are selectively incapable of undergoing rever-
sal of anergy, whereas others (Vb81/Va111 and Vb161/
Va111) are able to undergo anergy reversal. Although this
is theoretically possible, we consider it unlikely.
Our data are consistent with previous reports that found
that tolerance to certain self-epitopes was incomplete and
that immunization with the cognate antigen could generate
an immune response (42–44). However, the responding T
cells that were elicited were of relatively low affinity. For
instance, immunization of beef insulin (BI) transgenic mice
with BI generated a BI-specific T cell response that re-
quired higher concentrations of antigen to be elicited than
the response elicited in nontransgenic mice (42). Similarly,
low-avidity CD8 T cell responses were obtained after im-
munization with a p53 self-epitope when p531 mice were
used. In contrast, p53-deficient mice generated a higher
avidity response (43). These reports suggest that when self-
tolerance is incomplete, active immunization with the un-
altered self-protein or an epitope derived from it can elicit a
response of low-avidity T cells that had escaped tolerance.
Our data extend these observations to situations in which
tolerance to the epitope in question is complete and cannot
be reversed by immunization with the native epitope but
can be overcome by immunization with a heteroclitic ana-
logue.
The hypothesis that termination of tolerance to pMCC
involves the stimulation of low-affinity clones that are nei-
ther tolerized nor stimulated by pMCC but can be stimu-
lated by the heteroclitic analogue, pMCC-A, requires the
further postulate that after stimulation by the heteroclitic
antigen, the affinity threshold for stimulation is lowered
such that restimulation with the tolerogen results in a recall
response. To test this postulate, we studied the response of
naive and previously primed MCC-specific transgenic T
cells to a ligand of presumably lower affinity, a TCR antag-
onist peptide. It was found that, whereas naive and primed
T cells responded with similar vigor to the wild-type ago-
nist peptide, only primed cells proliferated in response to
stimulation with the antagonist peptide. This finding fur-
ther supports the low-affinity T cell model of breaking tol-
erance. The mechanism by which priming results in a low-992 Breaking Tolerance to an Immunodominant Epitope by Heteroclitic Antigens
ering of the affinity threshold for TCR-mediated
stimulation is unknown. One possible factor that could in-
fluence the sensitivity of the T cell response is the level of
expression of the CD4 coreceptor. Several studies have
documented that T cell clones with the same TCR have
heightened responses to suboptimal concentrations of ago-
nist peptide when the T cell is CD41 compared with
CD42 variants or when CD41 cells are pretreated with
anti-CD4 antibodies (45–48). Although we have not been
able to document any differences in the level of expression
of CD4 on the naive and recently primed T cells that we
analyzed (data not shown), it is possible that CD4 function
differs in the two cell types; e.g., the activity of the CD4-
associated Lck may be greater in primed compared with
naive T cells. This and other possible differences between
naive and recently primed T cells that may be important in
the conversion of TCR antagonists into agonists are being
investigated.
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